Armistice Capital, LLC Enlivex Therapeutics Ltd. Transaction History
Armistice Capital, LLC
- $6.56 Billion
- Q1 2025
A detailed history of Armistice Capital, LLC transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Armistice Capital, LLC holds 1,781,931 shares of ENLV stock, worth $2.8 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,781,931
Previous 2,208,000
19.3%
Holding current value
$2.8 Million
Previous $2.56 Million
32.53%
% of portfolio
0.03%
Previous 0.04%
Shares
4 transactions
Others Institutions Holding ENLV
# of Institutions
28Shares Held
3.13MCall Options Held
44.3KPut Options Held
7.1K-
Israel Englander Millennium Management LLC | New York, Ny669KShares$1.05 Million0.0% of portfolio
-
Morgan Stanley New York, NY231KShares$362,1750.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny168KShares$264,3750.0% of portfolio
-
Jane Street Group, LLC New York, NY80.8KShares$126,7910.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il70.1KShares$110,1130.0% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $28.9M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...